Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in two upcoming investor events in September 2025.
CEO Shalabh Gupta will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 8:30 a.m. ET, followed by another fireside chat at the Truist Securities Virtual event on September 17 at 10 a.m. ET. Webcasts will be available on the company's investor relations website.
Unicycive Therapeutics (Nasdaq: UNCY), società biotech in fase clinica focalizzata sui trattamenti per le malattie renali, ha annunciato la sua partecipazione a due eventi per investitori previsti per settembre 2025.
Il CEO Shalabh Gupta prenderà parte a una conversazione informale al H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre alle 8:30 ET, e a un secondo intervento in formato fireside all'evento virtuale Truist Securities il 17 settembre alle 10:00 ET. I webcast saranno disponibili sul sito web delle relazioni con gli investitori della società.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotecnológica en fase clínica centrada en tratamientos para enfermedades renales, ha anunciado su participación en dos eventos para inversores en septiembre de 2025.
El CEO Shalabh Gupta participará en una charla informal en la H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre a las 8:30 a.m. ET, y en otra charla informal en el evento virtual de Truist Securities el 17 de septiembre a las 10:00 a.m. ET. Los webcast estarán disponibles en la web de relaciones con inversores de la compañía.
Unicycive Therapeutics (Nasdaq: UNCY), 신장 질환 치료제 개발에 주력하는 임상 단계 바이오텍 기업이 2025년 9월 개최되는 두 차례의 투자자 행사 참가를 발표했습니다.
CEO 샬라브 굽타(Shalabh Gupta)는 9월 10일 오전 8:30(ET)에 열리는 H.C. Wainwright 27th Annual Global Investment Conference에서 파이어사이드 토크(대담)에 참가하고, 9월 17일 오전 10:00(ET)에 열리는 Truist Securities의 가상 행사에서도 또 다른 대담에 참여할 예정입니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 시청하실 수 있습니다.
Unicycive Therapeutics (Nasdaq: UNCY), une biotech en phase clinique axée sur les traitements des maladies rénales, a annoncé sa participation à deux événements investisseurs en septembre 2025.
Le PDG Shalabh Gupta participera à une discussion informelle lors de la H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre à 8h30 ET, puis à un second entretien informel à l'événement virtuel de Truist Securities le 17 septembre à 10h00 ET. Les webcasts seront disponibles sur le site relations investisseurs de la société.
Unicycive Therapeutics (Nasdaq: UNCY), ein klinisch fortgeschrittenes Biotech-Unternehmen mit Schwerpunkt auf Nierenerkrankungen, hat seine Teilnahme an zwei Investorenveranstaltungen im September 2025 angekündigt.
CEO Shalabh Gupta wird am 10. September um 8:30 Uhr ET an einem Fireside-Chat auf der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen und am 17. September um 10:00 Uhr ET an einem weiteren Fireside-Chat beim virtuellen Event von Truist Securities. Webcasts stehen auf der Investor-Relations-Website des Unternehmens zur Verfügung.
- None.
- None.
LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Type: Fireside chat
Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET
Event: Truist Securities Virtual Fireside Chat
Date/Time: Wednesday, September 17, 2025, at 10 a.m. ET
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your conference representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Conference?
What type of events will Unicycive (UNCY) participate in during September 2025?
How can investors access Unicycive's (UNCY) September 2025 presentations?
What is Unicycive Therapeutics' (UNCY) main focus area?
